| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| M0244 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
733 |
716 |
$630K |
| M0248 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
227 |
225 |
$172K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,542 |
1,536 |
$141K |
| M0223 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
101 |
101 |
$71K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
80 |
80 |
$28K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
88 |
88 |
$27K |
| M0246 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency |
28 |
28 |
$25K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
23 |
23 |
$5K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
25 |
25 |
$163.28 |